(redirected from Alkylating agents)
Also found in: Medical, Encyclopedia.
Related to Alkylating agents: Antimetabolites


tr.v. al·kyl·at·ed, al·kyl·at·ing, al·kyl·ates
To add one or more alkyl groups to (a compound).

al′kyl·a′tion (-kə-lā′shən) n.


1. (Chemistry) the attachment of an alkyl group to an organic compound, usually by the addition or substitution of a hydrogen atom or halide group
2. (Chemistry) the addition of an alkane hydrocarbon to an alkene in producing high-octane fuels


(ˌæl kəˈleɪ ʃən)

1. the replacement of a hydrogen atom in an organic compound by an alkyl.
2. the addition of an alkane to an alkene.
References in periodicals archive ?
The drug is currently not approved for the treatment of multiple sclerosis but is indicated for treating B-cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and who have failed fludarabine therapy.
The final section of the text is dedicated to molecular principles applied to specific toxicants and includes chapters on alkylating agents and "mustards," oxidative stress in the erythrocyte, aromatic amines and related toxic compounds, polycyclic aromatic hydrocarbon carcinogens, and acetaminophen.
At one TRC member institution, the Massachusetts Institute of Technology (MIT), researchers are focusing their attention on the effects of simple and complex alkylating agents, a class of DNA-damaging environmental toxins and toxicants that cause cell death, mutations, birth defects, and cancer.
Alkylating agents are thought to work by producing free radicals in cancer cells and, in theory, antioxidants would interfere with this action.
Predisposition to treatment-related AML is primarily due to chemotherapy with alkylating agents (nitrogen mustard, cyclophosphamide, procarbazine) or epipodophyllotoxins (etoposide, teniposide) (Table 3).
He and a team of researchers have developed a way to measure the ability of particular cancer cells to repair the damage done to DNA by a category of commonly utilized anti-cancer drugs that are known as alkylating agents, including nitrosourea and cisplatinin.
Using these and other factors, the retrospective study of more than 9,000 patients provides strong statistical evidence that approximately half of the secondary bone cancers observed can be blamed on radiation therapy or on chemotherapeutic alkylating agents such as the frequently prescribed cyclophosphamide.
Radiotherapy and chemotherapy with alkylating agents (e.
The classes of chemical compounds that cause cancer--including alkylating agents, DNA-damaging agents, and toxicants that affect the cell cycle--vary in the mechanisms by which they cause the disease.
PredictMDx for Glioblastoma, MDxHealth's most advanced epigenetic assay is designed to identify newly diagnosed GBM patients most likely to benefit from treatment with alkylating agents.
CHRONOS-2: A Phase III randomized, double-blind, placebo-controlled study of copanlisib in rituximab-refractory indolent NHL patients who have previously been treated with rituximab and alkylating agents (NCT02369016).